CD274 and cervical carcinoma: Taking into account the promising results reported from PD-1/PD-L1 inhibitors in the treatment of high-risk HPV-mediated cervical cancers (104), the efforts are now directed toward combination therapy with PD-1 pathway blockers and E6/E7-targeted therapy.